Research Article
Improvements in the Quality of Life of Patients with Myasthenia Gravis with Thymoma Who Underwent Video Thoracoscopic Thymectomy
Miguel Congregado*, Nathalie Pinos, Sergio Moreno-Merino and Rafael Jimenez-Merchan
Department of General Thoracic Surgery, Virgen Macarena University Hospital, Spain
*Corresponding author: Miguel Congregado, Department of General Thoracic Surgery, Virgen Macarena University Hospital, Av. Dr. Fedriani, 3, 41009 Seville, Spain
Published: 03 Mar, 2017
Cite this article as: Congregado M, Pinos N, Moreno-
Merino S, Jimenez-Merchan R.
Improvements in the Quality of Life
of Patients with Myasthenia Gravis
with Thymoma Who Underwent Video
Thoracoscopic Thymectomy. Clin Surg.
2017; 2: 1318.
Abstract
Introduction: Thymectomy as part of Myasthenia Gravis treatment has been proved to produce
total o partial clinical remissions. But almost always, parameters to measure this outcome have
been quantitative, as the amount of medication, presence or absence of symptoms. Very important
factors of the psychosocial field as real determinants of quality of life after surgery in this kind of
patients have been less investigated. We present a qualitative study of outcome after thymectomy in
non-thymomatous Myasthenia Gravis.
Methods: We performed a retrospective qualitative study to know the improvement in the quality of
life after thymectomy in non-thymomatous Myasthenia Gravis patients. Seventeen patients met the
inclusion criteria from January 2003 to December 2013 (extended thymectomy, Myasthenia Gravis
confirmed, non-thymomatous, over 18 years old). We applied the SF-36 Questionnaire and the
collected data were tabulated and analysed with SPSS 22.0. The Wilcoxon test for non-parametric
data was used to compare quality of life changes after surgery.
Results: Quantitative surgical outcome of these patients was: 52.9% had significant clinical
improvement with Oosterhuis scale (total remission n=5, mild symptoms n=3, mild disability n=1).
17.6% had Complete Stable Remission without medication, 35.2% had pharmacological remission
with low doses. All areas of SF-36 Questionnaire improved their median value after thymectomy,
with p< 0.05.
Conclusion: It seems that there is an improvement of quality of life in patients suffering Myasthenia
Gravis after extended thymectomy. There are better median results of all fields of the SF-36
Questionnaire after surgery, statistically significant.
Keywords: Myasthenia Gravis; Thymectomy; Quality of life
Introduction
Myasthenia Gravis (MG) has been connected to alterations in the thymic gland since
Oppenheim published the results of the autopsy of a myasthenic patient in which he found a thymic
tumour. Since then, this connection has been getting recognition, and today thymetoctomy is
indicated for young myasthenic patients that do not respond to medical treatment, above all in the
first years after the diagnosis. The goal is to completely remove the thymus, along with the fat that
surrounds it, through median sternotomy, thoracotomy, cervicotomy or video thoracoscopy. In
many cases, the surgery stabilizes the disease, reduces, the medication and appearance of myasthenic
crises, but this benefit does not show itself immediately right after surgery but progressively after
months or years [1-7].
Several studies have been published trying to clarify the benefits this technique has provided,
describing remissions that go from being partial to total, but they only took into account quantitative
parameters such as medication, or the presence or absence of symptoms, ignoring a very important
factor such the amount of obvious benefits the patient experiences at a psychosocial level, and these
are the true determinants of the changes in the quality of life after surgery. The goal of this study is to
get to know these changes in the quality of life of MG patients after thymectomy without thymoma.
Material and Methods
A descriptive retrospective qualitative research study was carried out to determine the improvement in the quality of life of MG patients without thymoma
who had undergone video thoracoscopic thymectomy from 2003 to
2013, prior consent of the ethical committee of Virgen Macarena
University Hospital, in Seville.
MG patients who were overage and had undergone an extended
Thymectomy were included and those with thymic tumors (Thymoma
or Thymus carcinoma …) and the ones who were diseased at the
moment of the study were excluded.
A research process took place across hospital records, concerning
the following variables: age, sex, Osserman group, pre and postsurgery
medication, definitive pathological anatomy, time that had
passed from diagnosis to surgery, Oosterhuis scale, Millichap scale and
post surgery MG Foundation of America scale. In order to determine
the changes in the quality of life, the SF-36 Questionnaire was
implemented, through a telephone survey, prior informed consent of
the patients. The two questionnaires (a pre-surgery SF-36, where they
were asked about their former situation, and a post-surgery SF-36,
where they were asked about their current situation) were filled out
at the same time (always in a period at least 12 months after surgery),
relying on the patients to remember what their situation was before
the surgery. This was the main limitation of our study (recall bias).
Statistical analyses
The data were tabulated and analyzed with the SPSS 22.0 program
and we resorted to the Wilcoxon test for the non parametric data to
compare the changes in the quality of life after surgery.
Table 1
Mg Classification Scale
To determine the clinical affectation of our patients, we used the
Osserman and Genkins scales.
Clinical scales to assess the success of surgery
To assess the response to surgery treatment, there are several
scales, being the Oosterhuis one among the most important (0:
total remission, 1: mild signs and symptoms, 2: mild disability, 3:
moderate disability, 4: severe disability and 5: the patient requires
respiratory support), the Millichap/Dodge scale (A: total remission
without medication, B: good response, with low medication dosage,
C: mediocre response with high dosage, D: without changes or
worsening and E: death) and the MG Foundation of America scale (RCE Complete Stable Remission: Absence of symptoms for at least
a year, RF pharmacological remission: Absence of symptoms for at
least a year through the use of any kind of pharmacological therapy,
and Mild Manifestations: the patient doesn’t show MG symptoms but
feels weakness in some muscles) [8-9].
Sf-36 scale of quality of life
The International Quality of Life Assessment (IQOLA) health
questionnaire was created in the nineties in the United States and
was translated into Spanish with the name SF-36. It consists of 36
questions (or items) that assess 8 levels of the state of health: Physical
function, Physical role, Body aches, Overall health, Vitality, Social
function, Emotional role and mental health. It is conceived for people
≥14 years old and can be done on your own or in the through an
interview (face-to-face or by telephone). For its assessment, the
results are converted into a scale that goes from 0 (the worst state of
health) to 100 (the best state of health) [10-15].
Table 2
Results
The group of study consisted of a total of 17 patients, 13 females
and 4 males, with an average age of 39±11.5 years. The surgery was
performed through thoracoscopy in every case, without showing
post-surgery complications. The pathological anatomy was that
of follicular hyperplasia in 10 patients (58.8%), thymolipoma in 4
(23.5%), atrophy in 2 (11.8%) and normal in 1 (5.9%). The medication
prior to the intervention was: anticholinergic drugs in 14 cases,
corticosteroids in 13, plasmapheresis in 1 and immunoglobulins in 1.
In every case, more than a year had passed from the MG diagnosis to
the surgery. In the years that passed between surgery and the moment
to fill out the questionnaire, we see that there is heterogeneity, with
an interval from 0 to 11 years. We found 7 patients (41.2%) who were
under 5 years old and 10 (58.8%) that had undergone the surgery
more than 5 before.
The results after thymectomy in the different scales are shown
in Table 1, where a change in the distribution per Osserman group
can be seen, from an initial value of 5 patients in stage 2B and 12
in 2B to a value of 5 patients without disease, 6 in stage 2A and 6 in
stage 2B. Therefore, there is a 29.4% (5 patients) with total remission,
an improvement of 50% in group 2B and 60% in group 2A, which
gives us a total of 52.9% (9 patients) with clinical improvement. In the Ossterhuisse scale we can observe that in 5 cases there was a complete
remission, in 3 mild symptoms and in 1 a mild disability, which
makes for a total of 9 patients with significative clinical improvement
and this matches with the data obtained with the Osserman group.
Concerning the need for post-surgery medication, there was a stable
complete remission (SCR) without medication in 3 patients and
good response with low dosages in 6 (pharmacological remission),
providing a total of 9 patients with positive response.
Pre and post-Surgery Values are expressed through average.
Statistical Significance in p< 0.05 values.
The changes in the quality of life are provided in Table 2, where
we can see an improvement on the average of all the other levels of the
SF-36 works with. In the physical function we can see an improvement
on the average that goes from 25 to 90, in the physical and emotional
role the average goes from 0 to 100, in the body aches from 32.5 to
55, in overall health from 30 to 65, in vitality from 25 to 50, in social
function from 25 to 53, and in mental health from 44 to 68. To finish
explaining the comparison between the quality of life before and after
surgery, p< 0.05 values were obtained in all levels, which makes these
changes statistically important.
Discussion
Myasthenia Gravis is a pathology that affects young people (20-
30 years old), and that causes a gradual decrease of the quality of life
in this population group with a decrease of the functions in physical,
social, working and emotional levels. After checking the bibliography,
we found out that there was a lack of studies similar to this. Most
of the literature we found determines that there was a good or bad
response after the thymectomy, relying only on the need for post
surgery medication and the presence of clinical Myasthenia [16].
Studies in which the quality of life of MG patients was measure
are: the works of Brush et al. [17] and Bachmann et al. [18] both
carried out in Hamburg at different times. The first one performed
in 1996 and its objective was to compare the quality of life of MG
patients that had undergone thymectomy and that got a positive
response to the surgery according to the Osserman scale in contrast
with the ones that did not get a response or changes after surgery.
A significative improvement was observed in the first group and in
the second, which was carried out in 2008, they compared the quality
of life of MG patients that had undergone thymectomy by video
thoracoscopy in contrast to the ones who were submitted to open
surgery, without observing major differences between the two groups.
None of the studies make a distinction of the cases with thymoma, the
ones without it, and the approach they took for the surgery.
These are the key areas of our study, given that there is a clear
evidence of thymectomy in patients with thymic tumor, being MG
patients or not, creating a doubt when there is no evidence of such
tumors. This is it because, nowadays, standardized management
protocols do not exist, given that we do not know with certainty how
beneficial surgery could be for this disease. Furthermore, open surgery
could determine a higher decrease in the quality of life in comparison
to video thoracoscopic surgery. So, despite the fact that these studies
provide a higher number of patients and assess the quality of life just
like we do, they are not investigating the same population, given that
their group is heterogeneous when it comes to surgical intervention,
surgical approach and ways to determine the improvement in the
quality of life.
As we can observe, the remission figures are changeable, this
can be caused by several factors such as the average of the age of the
patients [3-19] (in our study 39±11.5 years), the time that passed
from diagnosis to surgery (the less time, the better results we obtain
[3-20]; in our study more than a year had passed since the diagnosis
was made, for all the patients) and the time between surgery and postoperative
assessment, because it has become evident that the studies
that provide mostly patients that had been submitted to a follow-up
of more than 5 years, get a better response [3-16-21]. Despite that,
the existent studies agree that there is a clinical and pharmacological
improvement post thymectomy, regardless of the surgical approach
that is carried out, with little changes regarding the incidence of
response that can be higher or lower depending on the series of cases
that had been assessed. And this leads us to think that thymectomy is
a useful therapeutic technique and must be considered as a part of the
therapeutic arsenal in MG patients [3,22,23].
As we can check, the studies are based on clinical and
pharmacological scales to decide if a patient has shown and better
or worse response, ignoring the patients’ perception of their own
state of health and disease. This is what our study is based on,
and we experienced an improvement in all the levels of the SF-36
Questionnaire. The levels that experienced a higher improvement
were the physical and emotional role, that increased their average
from 0 to 100 points, which implies going from being in their worst
state of health to their best, taking into account that the physical role
is one of the most affected levels in MG patients, and this change is a
highlight of our work. The physical function was another aspect that
showed a significant increase of its average from 25 to 90, and this is
precisely one of the main factors that restrict the performance of MG
patients. Through these results we can see that, despite not showing
an improvement in all the cases following the clinical scales, this
result has changed the quality of life of the patients and has helped them improve it exponentially.
Apart from the aforementioned aspects that were the ones who
showed the most remarkable changes, we cannot forget the changes
on the average of body aches, that went from 32.5 to 55, overall
health from 30 to 65, vitality from 25 to 50, social function from 25
to 53, and mental health from 44 to 68. A statistical significance was
found in all of the changes detected in the different levels of the SF-36
Questionnaire.
To conclude, focusing on the results of our study, it would be
advisable to elaborate a study with a higher number of samples in
order to firmly affirm that thymectomy provides an important change
in the quality of life of MG patients. This is why our work must be
considered the onset for a larger project that would be able to involve
the overall population.
Therefore, out of the results of this work, we can conclude that:
-Thymectomy, as a treatment for the MG, provides a clinical
improvement with a complete or partial decrease of medication.
-According to the SF-36 Questionnaire, MG patients show a low
quality of life
-An improvement in the quality of life of MG patients is seen
after thymectomy is applied, with an increase of the average in all
aspects: physical function, physical role, emotional role, body aches,
overall health, vitality, social function and mental health, with a p<
0.05 value.
References
- Shields T, LoCicero J, Ponn R, Rusch V, General Thoracic Surgery, 6th ed. Lippincott Williams & Wilkins: 2005; 2617-2637.
- Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the ocurrence of remissions following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Phychiatry. 1991; 54: 406-411.
- Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymectomy in myasthenia gravis: results of 662 cases operated upon in 15 years. Eur J Cardiothorac Surg. 1989; 3: 504-511.
- DeFilippi VJ, Richman DP, Ferguson MK. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg. 1994; 57: 194-197.
- Vázquez-Pelillo J, Gil Alonso J, Díaz-Agero P, García Sánchez-Girón J, Roca Serrano R, Díez Tejedor E, et al. Prognostic factors and outcome of thymectomy in 80 cases of myasthenia gravis. Arch Bronconeumol. 2001; 37: 166-171.
- Loscertales J, Ayarra J, Congregado M, Arroyo A, Jiménez R, Girón J, et al. Video-assisted thoracoscopic thymectomy for the treatment of myasthenia gravis. Arch Bronconeumol. 2004; 40: 409-413.
- Loscertales J, Jiménez M, Arenas C, García D, Girón J, Congregado M. Tratamiento de la miastenia gravis mediante timectomíatoracoscópica. técnica y resultados iniciales. Arch Bronconeumol. 1999; 35: 9-14.
- Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, FagerstromRP, Pozner J, et al. Effects of thymectomy in myasthenia gravis. Ann Surg. 1987; 206: 79-88.
- Oosterhuis HJ. The natural course of Myasthenia gravis: a long-term follow-up study. J NeuroNeurosurg Psychiatry. 1989; 52: 1121-1127.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) (I). Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
- Ware JE. SF-36 health survey update. Spine. 2000; 25: 3130-3139.
- Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002; 324: 1417.
- Alonso J, Prieto L, Anto JM. SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. MedClin (Barc). 1995; 104: 771-776.
- Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al. The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments. Gaceta sanitaria. 2005; 19: 135-150.
- Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: manual and interpretation guide. Boston: New England Medical Center. 1993.
- Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016; 375: 511-522.
- Busch C, Machens A, Pichlmeier U, Emskotter T, Izbicki Jr. Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann Surg. 1996; 224: 225-232.
- Bachmann K, Burkhardt D, Schreiter I, Kaifi J, Busch C, Thayssen G, et al. Long-term outcome and quality of life after open and thoracoscopicthymecyomy for myasthenia gravis: analysis of 131 patients. Surg Endoscop. 2008; 22: 2470-2477.
- Diaz A, Black E, Dunning J. Is thymectomy in non-thymomatous myasthenia gravis of any benefit? Interact Cardiovasc Thorac Surg. 2014; 18: 381-389.
- Manlulu A, Lee TW, Wan I, Law CY, Chang C, Garzon JC, et al. Video-assisted thoracic surgery thymectomy for nonthymomatous myasthenia gravis. Chest. 2005; 128: 3454-3460.
- Freeman RK, Ascioti AJ, Van Woerkom JM, Vyverberg A, Robison RJ. Long-term follow-up after robotic thymectomy for non thymomatous myasthenia gravis. Ann Thorac Surg. 2011; 92: 1018-1022.
- Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, KobayashiM, et al. Extended thymectomy for myasthenia gravis patients: a20-years review. Ann Thorac Surg. 1996; 62: 853-859.
- Park IK, Choi SS, Lee JG, Kim DJ, Chung KY. Complete stable remission after extended transsternalthymectomy in myasthenia gravis. Eur J Cardiothorac Surg. 2006; 30: 525-528.
- Keijzers M, De Baets M, Hochstenbag M, Abdul-Hamid M, ZurHausen A, Van Der Linden M, et al. Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes. Eur J Cardiothorac Surg. 2015; 48: 40-45.
- Cakar F, Werner P, Augustin F, Schmid T, Wolf-Magele A, Sieb M, et al. A comparison of outcomes after robotic open extended thymectomy for myasthenia gravis. Eur J Cardiothorac Surg. 2007; 31: 501-504.
- Meacci E, Cesario A, Margaritora S, Porziella V, Tessitore A, Cusumano G, et al. Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. Eur J Cardiothorac Surg. 2009; 35: 1063-1069.